Biotechnology Collaborations: Does Business Model Matter?

Journal of Management and Governance, 16(3): 377-392, 2012. DOI/10.1007/s10997-010-9156-z

20 Pages Posted: 24 May 2019

See all articles by Raphael Greiner

Raphael Greiner

Roche Diagnostics International AG

Siah Hwee Ang

Victoria University of Wellington

Date Written: 2012

Abstract

This study investigates how a biotechnology firm’s collaboration incidence is affected by the business model it adopts. Specifically, we compare interfirm collaboration conducted by biopharmaceutical firms adopting the hybrid business model with those using the product-focused business model. The analysis based on 1,820 collaborations conducted by 87 dedicated biopharmaceutical firms suggests that firms adopting the hybrid business model generally engage in more collaboration. They also establish a greater proportion of exploration collaboration. These findings have implications for firm’s positioning using business models.

Keywords: Business model, Collaboration, Biotechnology, Value chain

Suggested Citation

Greiner, Raphael and Ang, Siah Hwee, Biotechnology Collaborations: Does Business Model Matter? (2012). Journal of Management and Governance, 16(3): 377-392, 2012. DOI/10.1007/s10997-010-9156-z, Available at SSRN: https://ssrn.com/abstract=3371271

Raphael Greiner (Contact Author)

Roche Diagnostics International AG ( email )

Forrenstrasse 2
Rotkreuz, CH-6343
Switzerland

Siah Hwee Ang

Victoria University of Wellington ( email )

P.O. Box 600
Wellington, 6140
New Zealand

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
35
Abstract Views
421
PlumX Metrics